- Home
- LVTX vs AKTX Comparison
LVTX vs AKTX Comparison
Compare LVTX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- AKTX
- Stock Information
- Founded
- LVTX 2016
- AKTX N/A
- Country
- LVTX Netherlands
- AKTX United States
- Employees
- LVTX N/A
- AKTX N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- AKTX Health Care
- Exchange
- LVTX Nasdaq
- AKTX Nasdaq
- Market Cap
- LVTX 33.1M
- AKTX 29.1M
- IPO Year
- LVTX 2021
- AKTX N/A
- Fundamental
- Price
- LVTX $1.29
- AKTX $1.42
- Analyst Decision
- LVTX Hold
- AKTX
- Analyst Count
- LVTX 3
- AKTX 0
- Target Price
- LVTX $1.75
- AKTX N/A
- AVG Volume (30 Days)
- LVTX 50.0K
- AKTX 15.2K
- Earning Date
- LVTX 05-14-2025
- AKTX 05-15-2025
- Dividend Yield
- LVTX N/A
- AKTX N/A
- EPS Growth
- LVTX N/A
- AKTX N/A
- EPS
- LVTX N/A
- AKTX N/A
- Revenue
- LVTX $4,990,000.00
- AKTX N/A
- Revenue This Year
- LVTX N/A
- AKTX N/A
- Revenue Next Year
- LVTX N/A
- AKTX N/A
- P/E Ratio
- LVTX N/A
- AKTX N/A
- Revenue Growth
- LVTX N/A
- AKTX N/A
- 52 Week Low
- LVTX $0.85
- AKTX $0.85
- 52 Week High
- LVTX $2.53
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- LVTX 51.81
- AKTX 58.06
- Support Level
- LVTX $1.18
- AKTX $1.20
- Resistance Level
- LVTX $1.34
- AKTX $1.37
- Average True Range (ATR)
- LVTX 0.08
- AKTX 0.09
- MACD
- LVTX 0.00
- AKTX 0.00
- Stochastic Oscillator
- LVTX 68.75
- AKTX 97.72
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).